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Abstract
Background: A considerable economic burden has been repeatedly associated with alcohol dependence (AD) –
mostly calculated using aggregate data and alcohol-attributable fractions (top-down approach). However, this
approach is limited by a number of assumptions, which are hard to test. Thus, cost estimates should ideally be
validated with studies using individual data to estimate the same costs (bottom-up approach). However, bottom-up
studies on the economic burden associated with AD are lacking. Our study aimed to fill this gap using the bottom-up
approach to examine costs for AD, and also stratified the results by the following subgroups: sex, age, diagnostic
approach and severity of AD, as relevant variations could be expected by these factors.
Methods: Sample: 1356 primary health care patients, representative for two German regions. AD was diagnosed by a
standardized instrument and treating physicians. Individual costs were calculated by combining resource use and
productivity data representing a period of six months prior to the time of interview, with unit costs derived from the
literature or official statistics. The economic burden associated with AD was determined via excess costs by comparing
utilization of various health care resources and impaired productivity between people with and without AD, controlling
for relevant confounders. Additional analyses for several AD characteristics were performed.
Results: Mean costs among alcohol dependent patients were 50 % higher compared to the remaining patients,
resulting in 1836 € excess costs per alcohol dependent patient in 6 months. More than half of these excess costs
incurred through increased productivity loss among alcohol dependent patients. Treatment for alcohol problems
represents only 6 % of these costs. The economic burden associated with AD incurred mainly among males and
among 30 to 49 year old patients. Both diagnostic approaches were significantly related to the economic burden,
while costs increased with alcohol use disorder severity but not with other AD severity indicators.
Conclusions: Our study confirms previous studies using top-down approaches to estimate the economic burden
associated with AD. Further, we highlight the need for efforts aimed at preventing adverse outcomes for health and
occupational situation associated with alcohol dependence based on factors associated with particularly high
economic burden.
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Background
Alcohol dependence (AD) is a prevalent disorder in
high-income countries, with 3.4 % of the adult popula-
tion in the European Union being alcohol dependent [1].
AD represents a major health burden for modern soci-
eties [2] because of high mortality rates [3–5], associated
disability [6] and prevalent comorbidities [7–9]. The
considerable health burden is also closely linked to an
economic burden for the society. The economic burden
is defined by the societal costs incurred by a given dis-
ease and is usually measured against a counterfactual
scenario which assumes that the given disease does not
exist [10]. The costs incurred by AD and heavy drinking
were estimated to amount to about 1 % of the European
gross domestic product [11]. For Germany, the eco-
nomic burden related to AD has not been estimated yet,
but the burden associated with alcohol in total were also
found to be around 1 % of the national gross domestic
product [12, 13].
While a number of other studies have estimated the
economic burden of alcohol in the EU in general, and
Germany in particular e.g. [12, 14–16], studies on the
economic burden of AD are more sparse as indicated in
a recent review [17]. The burden of AD was found to be
related to direct health care spending, e.g. for hospitali-
zations and medications, as well as to indirect costs
associated with unemployment and absenteeism. The
authors call for more cost-of-illness studies as they iden-
tified several shortcomings in the data. More detailed es-
timates are necessary to justify public spending, e.g. for
planning and implementing public health programs to
reduce the burden of addiction.
Cost-of-illness studies usually lack empirical assess-
ments of health care utilization and therefore
combine aggregated data with alcohol-attributable
fractions (top-down method) to determine the share
of alcohol consumption or alcohol dependence in
cause-specific mortality and hospitalizations [2]. How-
ever, this approach is limited by a number of assump-
tions. First, alcohol-attributable fractions denote the
proportion of cases attributable to all alcohol con-
sumption by definition, usually derived from the
distribution of average drinking levels and associated
relative risks [18]; thus, they cannot be used to evalu-
ate costs related to certain drinking patterns or
alcohol-related diagnoses without being adjusted to
the relevant category e.g. [11]. Second, it is assumed
that risk functions employed in the calculation of
alcohol-attributable fractions, developed from pub-
lished meta-analyses based on systematic literature re-
views that included international literature, can be
applied to specific countries. Third, aggregate data
usually include a number of estimates of different
sources and thus reproduce their measurement errors.
Cost-of-illness studies that collect individual data (bot-
tom-up method) do not rely on these assumptions and
have thus the advantage of directly calculating the eco-
nomic burden, making them a benchmark against which
other studies using the top-down method can be com-
pared with. Additionally, unlike studies relying on aggre-
gate data, studies employing the bottom-up method
generally allow for a more detailed calculation and sep-
aration of costs for specific subgroups for which
population-attributable fractions are not available. The
economic burden of a given disease is estimated by com-
paring mean costs of diseased and healthy individuals,
which results in excess costs. While this approach suits
well to determine costs due to morbidity and disability,
it can hardly assess costs related to mortality, which
should be considered [10] as they make up a substantial
share of the economic burden associated with AD [11].
To date, previous studies have used bottom-up ap-
proaches to estimate the economic burden for some dis-
eases e.g. [19, 20]; however, for AD, studies using this
method in sufficiently large and representative samples
are very sparse [for a systematic review of international
cost-of-illness studies, see [11], for reviews of European
cost-of-illness studies, see [17, 21]. Thus, using a
bottom-up approach, the present studies’ primary aim
was to estimate the economic burden of AD and to
compare those estimates with previous top-down esti-
mations, which suggest that indirect costs make up at
least half of AD related costs in most countries [2, 11].
Previous estimates also indicated that 70 % of the eco-
nomic burden related to alcohol consumption in
Germany were caused by males [12], which is very simi-
lar to the sex ratio in AD diagnoses [1]. However, as this
proportion varied considerably across various cost cat-
egories, a sex-stratified examination of the economic
burden was considered important. Similarly, age was
regarded a relevant factor the economic burden because
the course of AD peaks at early ages [22] and interac-
tions of AD-associated somatic comorbidities with age
have been suspected [23].
For the purpose of estimating the economic burden
associated with AD, we analysed a sample of German
primary care patients from the ‘Alcohol Dependence in
Primary and Specialist Care in Europe’ (APC) study [7,
24]. We identified two important AD characteristics that
could influence the economic burden associated with
AD. First, previous reports of the APC study showed
that patients diagnosed with AD either through a stan-
dardized instrument assessing DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders, fourth edition)
diagnoses [25] or through clinical judgements from the
treating general practitioner (GP) made up two relevant
but largely distinct groups of alcoholics [7]. As GP
diagnosed patients were older and reported more
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comorbidities than patients with DSM-IV diagnoses,
separate cost examinations for both diagnostic groups
seemed reasonable. Second, the AD associated economic
burden was expected to vary by AD severity as measured
by the number of DSM-5 (Diagnostic and Statistical
Manual of Mental Disorders, fifth edition) alcohol use
disorder (AUD) criteria [26], drinking levels [27], or
treatment for alcohol problems [28] because these indi-
cators were found to be related to adverse mental and/
or physical consequences as well as disability and mor-
tality [4, 23, 28–30]. It may seem counterintuitive to
consider alcohol treatment as indicator for severity but
low treatment rates [31] and increased degree of impair-
ment [32] suggest that only the most severe cases seek
treatment. Given the associations with comorbidity, dis-
ability and mortality, it was expected that health care
spending and impaired productivity would increase with
AD severity. Thus, additional analyses should serve to
measure the impact of the diagnostic approach and of
different indicators of AD severity on the economic bur-
den associated with AD.
In conclusion, the present studies’ primary objective
was to estimate the cost-of-illness of AD patients, from
a societal German primary care perspective using a
bottom-up approach. The results were compared to pre-
vious estimates of German cost-of-illness studies of alco-
hol that used a top-down approach. In addition, this
study stratified the results by sex and age, and per-
formed additional analyses to examine the impact of AD
characteristics (diagnosis and severity).
Methods
APC study design and participants
The APC study was designed to gain knowledge about
the distribution, recognition, and treatment of AD in
European primary health care settings. Previous results
of the study indicate that AD among primary care pa-
tients was characterized by low socioeconomic status,
unemployment, co-morbidities, mental distress, and dis-
ability [32]. For the study, a representative sample of
GPs was drawn in six European countries (Germany,
Hungary, Italy, Latvia, Poland, and Spain), after approval
was obtained from the concerning ethic committees in
all countries (Germany: approval gained on August 28,
2012; reference number: EK 207072012).
GPs assessed patients aged 18–64 on one day or more
than one consecutive days using a brief questionnaire,
which focused on the patients’ health and included
alcohol-related questions as well as present, and lifetime
AD diagnoses. A probability sample of all assessed pa-
tients was then drawn while oversampling patients per-
ceived to have alcohol problems or AD by their GP.
Sampled patients were further interviewed using a range
of standardized instruments including the Composite
International Diagnostic Interview CIDI; [33] which is
the gold standard in assessing DSM-IV diagnoses [34]. It
was previously shown that both CIDI and GPs diagnosed
a similar proportion of individuals, with differences in
age and comorbidities and overall little overlap between
both groups [7]. As both approaches were judged valid,
they were combined into a mutual AD category. Re-
spective diagnoses were based on the 12-month time
frame prior to the interview. The CIDI also assessed the
patients’ drinking behavior with a quantity-frequency ap-
proach [35], which could be combined to form daily
drinking levels as measured in standard drinks per day
(one standard drink equals 10 g pure ethanol).
Furthermore, the patient interview also included the
World Health Organization Disability Assessment
Schedule (WHODAS) 2.0 [36] to assess sociodemo-
graphic variables and the degree of disability, the Kessler
Psychological Distress Scale (K10), and a service use
questionnaire adapted from the United Kingdom Alco-
hol Treatment Trial (UKATT) [37], which can be found
in Additional file 1.
The German population sample of the APC study was
identified by primary health care GPs from the ‘National
Association of Statutory Health Insurance Physicians’
(“Kassenärztliche Bundesvereinigung”) (response rate at
GP level: 36.7 %) who were practicing in two German
regions: Berlin-Brandenburg (46.1 % of all GPs) and
eastern Saxony (53.9 % of all GPs). Interviews with pa-
tients were conducted mainly via telephone (response
rate at patient level: 75.7 %) between March 2013 and
January 2014. All patients gave informed consent prior
to being interviewed. A more detailed description of the
APC study, its sampling design and instruments used
can be found elsewhere [7, 24].
Cost assessment
In order to determine the costs for each patient, we
combined individual resource use and productivity data
with respective unit costs. For example, in order to de-
termine the costs of GP visits, we multiplied the number
of visits with the costs of a single visit. All resource use
data was collected via the patient interview and included
hospital attendances, general practice visits, home care
by healthcare and support professionals, medication use,
and alcohol services use. If respondents felt that their
type of contact was not part of the provided categories,
they could specify the number of ‘other’ contacts. Most
of these responses could be classified into existing or
new categories based on their specification. If the speci-
fication was missing, the contacts were not included in
determining respective costs.
Additionally, productivity data was also assessed
through the interview and encompassed questions on
the patients’ employment status and their absenteeism
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in the workplace. Most of these data were assessed using
the UKATT questionnaire [37]. All questions in this in-
strument referred to a six months period prior to the
interview, which was the default period in the original
version of the questionnaire. We considered this period
sufficiently long to gather important information about
health care utilization and productivity, while being
short enough to keep potential memory bias at a
minimum.
These resource use and productivity data were then
combined with German unit costs following a bottom-
up approach, in compliance with the guidelines of the
‘Working Group Methods in Health Economic Evalu-
ation’, which lists standard unit costs for health economy
evaluations in Germany [38]. The majority of unit costs
could be taken from their publication, while the
remaining unit costs were taken from statistics and pub-
lications by official agencies or health insurance com-
panies. All costs were updated to 2014-€ using the
consumer price index [39]. For health care unit costs,
we used health care specific price changes; for costs re-
lated to productivity, overall price changes were used.
Unit costs in 2015-€ were deflated using the average rate
from the first 10 months of the year 2015. A detailed de-
scription of all resource use components, their updated
unit costs, and related sources are presented in
Additional file 2: Web Table 1.
Direct costs
Hospital attendances For hospital attendance rates, we
assessed up to three (limit given by UKATT question-
naire) department-specific inpatient admissions, out-
patient visits, day case surgery attendances, and accident
and emergency attendances. Unit costs were derived
from the guidelines for health economic evaluation in
Germany [38]. For inpatient and outpatient visits, we
used department-specific unit costs and mean costs if
department-specific unit costs could not be assigned to
the reported department. In Germany, separate day case
surgery attendances generally do not exist and were thus
rarely reported by the patients (6 % with at least one at-
tendance). Day case surgery and outpatient visits were
valued alike. Unit costs for accident and emergency at-
tendances were equal to mean inpatient admission costs
for patients who were admitted to the hospital following
the treatment. For patients who received treatment in
the accident and emergency department only, the re-
spective department-specific outpatient unit costs were
used. Therefore, all hospital-related costs could be
grouped as either inpatient or outpatient costs.
General practice visits We assessed the number of sur-
gery and home visits, as well as practice nurse contacts
(at the surgery) for each patient, while GP and nurse
contacts were collapsed into a single category. Unit costs
for personal patient contacts and home visits were taken
from the standard evaluation criteria (Einheitlicher
Bewertungsmaßstab) [40] – a catalogue on the costs of
services reimbursed by the statutory health insurance to
the respective health professionals. As appropriate in the
German context [38], these costs had to be adjusted to
the share of private health insurances in outpatient
health care settings. For this reason, we updated the ra-
tio of the share of patients covered by statutory health
insurance [41] to the share of total revenue made by
statutory health insurance companies [42], which re-
sulted in a factor of 1.03 – smaller than the factor used
by Krauth and colleagues [38] (1.11).
Home care by healthcare and support professionals
In this section, we asked patients for the number of
home contacts by health professionals, including occu-
pational therapists, support workers, social workers,
community psychiatric nurses, district nurses, and other
professionals, where patients specified using the service
of physiotherapists and alternative practitioners. Unit
costs for these services were drawn from different
sources: For services provided by occupational thera-
pists, we referred to the mean cost of various services at
the patients’ home remunerated by different statutory
health insurances in Berlin [43], after being weighted by
the share of patients in the respective insurance com-
panies [44], and adjusted with the above specified ratio
for the share of private health insurances. Costs of a
home session with a physiotherapist are based on the
guidelines for health economic evaluations in Germany
[38], and with a home visit charge added [45]. Unit costs
for home visits from alternative practitioners were taken
from a separate remuneration system which provides
commonly used charges for different treatments [46].
Contacts with other health care professionals (e.g. social
workers) were valued using the mean costs of occupa-
tional therapists, alternative practitioners, and physio-
therapists. Lastly, the costs of paid homemakers
providing household support were determined using the
mean gross income of other labour forces [47].
Medication use For prescribed medication, we assessed
brand names, size of each dose (in mg), frequency of
doses per day, and period of intake of up to five medica-
tions per patient (limit was predetermined by the
UKATT questionnaire and was reached by 7.5 % of all
patients). The cost of each medication was determined
by multiplying costs per day with period of intake. While
period of intake was directly assessed, costs per day were
based on costs per dose (estimated by identifying price
and size of available medication packages in the red list
[48] or online pharmacies) and the reported dose or, if
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missing, the defined daily dose [49]. Additional file 2:
Web Figure 1 describes these steps in detail (see
Additional file 2).
Taken together, two core variables were needed to cal-
culate medication costs: a) medication costs per day
multiplied with b) period of medication intake. This data
was only available in association with 37 % of all re-
ported medications, mainly because the exact brand
names were not given for 61 % of all reported medica-
tions, but instead their prescribed purpose or another
reference category (e.g. hypertension medication, contra-
ceptive, etc.). Because assessment of costs per package
without a valid trade name were not feasible, the re-
spective costs per day were unavailable. Therefore, we
imputed the costs per day by using the median of the re-
spective costs of similar medications of the same cat-
egory identified via the ‘Anatomical Therapeutic
Chemical’ code. Using the median allowed us to impute
conservatively and be less affected by outliers of very
costly medications. A similar procedure was applied to
missing values of period of intake (5.7 % of all reported
medications), for which the mean period was imputed
among the same category of drugs. One case reported
using a very costly drug (calculated costs: 315659.30€ in
the 6-month observed period). In order to make sure that
this outlier would not overly inflate the medication costs,
we decided to adjust the costs to 150 % of the second
highest single medication cost (adjusted costs: 7328€).
Alcohol specific services use Alcohol specific individ-
ual or group contacts with GPs or their nurses, with al-
cohol agencies, at residential rehabilitation institutions,
at hospitals, with self-help groups, and other contacts
were assessed. All reported contacts were grouped into
GP contacts, inpatient admissions (in residential re-
habilitation institutions or hospitals), outpatient visits (at
hospitals or alcohol agencies), counselling (at alcohol
agencies, e.g. with psychotherapists) and group therapies.
Alcohol-related GP contacts were valued as any other
GP visit with unit costs taken from the standard evalu-
ation criteria [40], and adjusted for the share of private
health insurances (as described above). The unit costs
for inpatient and outpatient treatment were retrieved
from the hospital based remuneration system for psych-
iatry and psychosomatic departments, referring to the
daily mean remuneration for inpatient and outpatient
treatment of AD, respectively [50]. Costs were deter-
mined based on the number of nights spent in the hos-
pital or based on the number of semi-residential
contacts, for inpatient and outpatients visits respectively.
For alcohol counselling contacts, unit costs were based
on contacts with psychotherapists and were taken from
the German guidelines for health economic evaluations
[38]. Unit costs of a single group therapy session were
considered equal to the opportunity costs of one-hour
leisure time of both the patient and the therapist. Op-
portunity costs were assessed via the gross average wage
in Germany in 2014 [47].
Indirect costs - productivity losses
We considered absenteeism, unemployment, and disabil-
ity or early retirement as indirect costs. First, respon-
dents were classified as employed (paid work or self-
employed), unemployed (but job seeking), or disabled/in
early retirement (including unemployment due to health
reasons) based on responses given in the WHODAS 2.0
sociodemographic section. Patients pursuing non-paid
work, studying, or homemaking in their own home were
not assigned any productivity-related costs, representing
17.2 % of all studied cases. The costs related to absentee-
ism among gainfully employed patients were estimated
using the friction cost approach [51] and a frictional
period of 49 days [38]. We referred to mean gross costs
of one working hour multiplied with the mean working
hours per day in 2013 [52] to assess the costs of one ab-
sent day. Costs related to unemployment could be re-
trieved from another study which took into account paid
benefits, reduced tax revenue, and reduced insurance
fees within statutory health and retirement insurances
[53]. We manually estimated costs related to unemploy-
ment due to health problems, disability, or early retire-
ment using the mean paid benefits for persons with
reduced working capacity [54] in addition to costs of re-
duced tax and fee revenue per unemployed person ac-
cording to the previously mentioned study [53]. This
estimation assumes similar patterns of reduced spending
among the disabled or early retirees compared to other
unemployed patients. Although the classification of em-
ployment status only refers to the time of the interview,
we generalized this classification to the six months prior
to the interview in order to be in line with the other
measures on direct and indirect costs. We did not in-
clude costs due to premature mortality because the de-
sign of this study did not allow for the assessment of
this parameter.
In addition to calculating productivity-related costs,
we also present descriptive statistics on presenteeism, i.e.
reduced capacity while being at work. We did not in-
clude a standardized measure to directly determine the
respective costs but collected information approximating
this concept: number of days with reduced or cut-back
work due to any health condition (WHODAS 2.0); num-
ber of days with at most half of the usual capacity due to
mental distress (K10); number of days with affected
productivity at work due to alcohol use (UKATT service
use questionnaire). These measures are presented de-
scriptively in order to grasp the magnitude of lost prod-
uctivity while being at work.
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Statistical analyses
As contextual information, descriptive statistics for
sociodemographic variables and the WHODAS sum
score as indicator for disability were presented for pa-
tients with AD diagnoses and for those without. We
tested for statistical differences by diagnostic status via
negative binomial regression (for the WHODAS sum
score) and via Chi2-Tests (for the remaining binary vari-
ables). The sampling design implied patients with alco-
hol problems or AD to be overrepresented in the
interviewed sample. This distortion was accounted for
by weighting all analyses with the inverse sampling
probability.
Primary aim: estimation of economic burden of AD
The economic burden associated with AD was deter-
mined via excess costs, which were calculated as mean
difference between patients with and without AD diag-
nosis by sex in the following sectors of direct and indir-
ect costs: inpatient admission, outpatient visit, any GP
visit, prescribed medication, home care, alcohol treat-
ment, absenteeism, unemployment, disability/early re-
tirement. Given the right skewed distribution of cost
variables, significant differences were tested using age-
adjusted negative binomial regressions for all count vari-
ables (most cost variables). Decisions for or against
utilization of zero-inflated models for variables with ex-
cess zeros, i.e. resources being utilized only by a minor-
ity of patients, were based on results from Vuong tests
and actual distribution. Zero-inflated models are nested
models predicting both the occurrence of any costs
(logit model) and the amount of costs (count model)
[55]. Thus, these models identify reasons for higher
mean costs by specifying whether (a) the proportion of
patients using any service differs (logit model) or
whether (b) there are any differences in the average
treatment costs among those reporting at least one con-
tact (count model). For costs associated with unemploy-
ment and disability/early retirement (binary/ordinal
variables), we employed logistic regressions. Since costs
related to disability/early retirement were sex-specific
and thus resulted in an ordinal scale (0: no costs, 1:
mean costs for males, 2: mean costs for females), we
used a binary variable indicating disability/early retire-
ment in order to conduct a logistic regression in the en-
tire sample. Age-stratified cost analyses were illustrated
by plotting the estimated costs for five consecutive age
groups of similar size (18–29, 30–39, 40–49, 50–59, and
60–64). Sex-adjusted negative binomial regressions on
the overall costs were run for each age group to examine
the differential impact of age.
Further, descriptive measures on presenteeism were
presented separately, as they could not be included in
the cost estimations. Sex-stratified differences between
patients with and without AD were tested by using age-
adjusted zero-inflated negative binomial regressions for
count variables (as above) and logistic regressions for
binary variables (at least one such day).
Sensitivity analyses
To test for the robustness of our results, we ran one-way
sensitivity analyses and varied the following assump-
tions: human capital approach instead of frictional cost
to assess costs due to absenteeism (main calculations);
only complete responses compared to complete & im-
puted responses (main calculations); and uniform annual
inflation rates (0 % vs. 5 %) [56] compared to the sector-
and year-specific rates (main calculations).
Additional analyses
To examine the impact of AD characteristics on the eco-
nomic burden, we performed additional analyses. For
both CIDI and GP diagnoses, costs were estimated sep-
arately and compared to the remaining sample without
the respective diagnosis using negative binomial regres-
sions adjusting for age and sex. Direct comparisons were
not immediately feasible as GP and CIDI diagnoses did
not result in two entirely distinct but in two slightly
overlapping groups [7]. As indicators for AD severity, we
referred to professional treatment (AD severity I; com-
bined assessment by GP and patient), as well as number
of DSM-5 AUD criteria (AD severity II; assessed by
CIDI) and daily drinking levels (AD severity III; assessed
by CIDI). For AD severity I, we examined excess costs
associated with treatment for AD among all diagnosed
patients using a binary indicator. For AD severity II and
III, separate models examined the association of each
continuous predictor with the respective costs among all
patients. For the latter models, direct (excess) cost esti-
mations for separate groups were not feasible as they did
not imply distinct groups for which costs could be esti-
mated for. All associations with individual costs and the
respective AD characteristics were determined with age
and sex adjusted negative binomial regressions for dir-
ect, indirect and overall costs.
Results
Sociodemographics
A detailed description of the entire APC sample can be
found in previous publications (Additional file 2 of
[32, 57]). For the German sample (N = 1,356), Table 1
presents sociodemographics by AD diagnosis. Mean pa-
tient age was 45 years and 56.9 % were female. AD diag-
noses by GP or CIDI were given to 17.0 % and 6.4 % of
all male and female primary care patients, respectively
(total: 11.0 %). Among patients with AD diagnoses,
males and patients who rated their socioeconomic status
above average were overrepresented, while an average
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socioeconomic status was less common in this group.
Further, AD cases showed higher disability levels as
compared to the remaining sample. No statistically sig-
nificant differences could be found for the distribution
of age and unemployment.
Resource use data
Resource use data were collected from the German APC
study for six months before the time of interview. De-
scriptive summary statistics of these data by AD and sex
can be found in Table 2. Among patients without AD
diagnosis, three patients (0.2 %) reported treatment for
alcohol problems, as compared to ten patients (7 %) in
the AD group.
Economic burden associated with AD
All presented costs represent the results from combining
collected resource use data from the German APC study
(Table 2) with German unit costs (Additional file 2).
Table 3 presents the direct and indirect costs by spend-
ing sector, AD and sex. Across all patients, we have esti-
mated that 3879.66€ of direct and indirect costs
incurred per patient. Of all costs calculated for the entire
sample (5405230.60€), 15 % incurred among patients
with an AD diagnosis (811767.45€). The economic bur-
den associated with AD was determined through the
mean cost difference between patients with and without
an AD diagnosis and equalled 1836.35€ per AD case (p
< .001; age adjusted). In comparison to direct costs,
productivity loss made up the larger share of this burden
(57 % of all costs). The three largest components of the
economic burden were disability/early retirement (27 %),
inpatient treatment (26 %) and unemployment (20 %),
which represented almost 75 % of the entire economic
burden associated with AD. Alcohol treatment consti-
tuted only about 6 % of this burden.
Sex- and age-stratified analyses
Sex-stratified analyses for both male and female AD pa-
tients found significant excess costs, too. Adding sex as
further covariate to the age-adjusted main model (see
Table 3) predicting total costs by AD diagnosis produced
a non-significant effect of sex (p = .558; other results not
shown). Fig. 1 illustrates total costs per patient by AD
diagnosis for consecutive age groups, with excess costs
amounting to 889.48€ (p = .099; 18–29 year old),
4211.53€ (p < .001; 30–39 year old), 3850.06€ (p = .006;
40–49 year old), 775.86€ (p = .373; 50–59 year old), and
715.26€ (p = .269; 60–64 year old).
Direct costs
We found higher direct costs due to health care
utilization among AD cases irrespective of including or
excluding alcohol treatment. Overall, 18 % of all direct
costs incurred among patients with an AD diagnosis. In-
patient treatment – not including specialized alcohol-
related hospitalization – produced the highest share of
mean direct excess costs (468.85€), followed by GP treat-
ment (120.34€) and alcohol-specific treatment (104.87€).
According to the results from the zero-inflated model,
excess costs in inpatient admissions were likely to be
due to a greater proportion of male AD cases reporting
any inpatient admission (logit model), while differences
in the costs of admissions were not found (count
Table 1 Sociodemographics and disability by AD diagnosis
All patients Non-AD AD pa
N = 1,356 N = 1,213 N = 143
Sex (% female, CI) 56.9 (54.2–59.5) 59.8 (57.1–62.6) 33.0 (25.3–40.7) <.001
Age (%, CI)
18–29 19.6 (17.5–21.7) 19.1 (16.9–21.3) 23.4 (16.5–30.3) .218
30–39 17.9 (15.9–20.0) 17.9 (15.7–20.1) 18.3 (12.0–24.6) .908
40–49 18.7 (16.6–20.8) 19.1 (16.9–21.4) 14.8 (9.0–20.7) .218
50–64 43.8 (41.2–46.5) 43.9 (41.0–46.7) 43.5 (35.3–51.7) .930
Unemployment (%, CI) 12.4 (10.6–14.1) 11.8 (9.9–13.6) 17.0 (10.8–23.2) .078
Socioeconomic status (%, CI)
Above average 20.1 (18.0–22.3) 19.3 (17.1–21.6) 26.8 (19.5–34.1) .037
Average 69.0 (66.5–71.5) 70.0 (67.5–72.6) 60.5 (52.5–68.6) .021
Below average 10.9 (9.2–12.5) 10.6 (8.9–12.4) 12.7 (7.2–18.2) .459
Disability score (WHODAS, mean, SD) 14.8 (14.7) 14.4 (14.4) 18.1 (16.2) .004
Note
AD Alcohol dependence, CI 95 % confidence interval, WHODAS World Health Organization Disability Assessment Schedule 2.0
adifference between AD and non-AD cases was determined using Chi2-Tests (F-distribution) for binary variables (sex, age categories, unemployment, socioeconomic
categories) and negative binomial regression for the count variable (WHODAS sum score)
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model). For home care related costs (excess costs per
male AD case: 85.08€), the results were the other way
round, with male AD patients being just as likely to re-
port any home care (logit model), but if they received
any home care, their costs were higher (count model)
than those of other male patients.
Results of direct mean cost differences among female
patients with or without an AD diagnosis were quite
mixed and not significant in most sectors, except for re-
ception of home care services. Only one female AD case
reported receiving some kind of home care, thus result-
ing in significant lower costs compared to other female
patients (−23.05€ per female AD case). Alcohol treat-
ment was found to make up the largest share of excess
costs among female AD cases (261.08€ per case), but
this was mainly due to a single case reporting 40 in-
patient nights which resulted in a large mean and stand-
ard deviation. Overall, the excess direct costs associated
with AD equalled 230.78€ per female patient but were
not significantly different from zero.
Indirect costs
Indirect costs due to absenteeism, unemployment and dis-
ability or early retirement were found to be concentrated
among AD cases, which were responsible for 14 % of all
indirect costs. On average, these costs were 1,050.97€
higher among AD cases as compared to other patients.
This finding was also reproduced in sex-stratified analyses
but not for all components of indirect costs. In total, indir-
ect costs account for more than half of all observed excess
costs, which is also demonstrated by Fig. 2.
We found that presenteeism was also more prevalent
among AD cases (see Table 4). Male patients with an AD
diagnosis reported more days with reduced work capacity
due to any health condition (WHODAS 2.0) or due to
mental distress (K10) as compared to non-AD cases. Fur-
ther, for both male and female patients, alcohol-associated
work impairment was present. While about 4 % of all
cases with a gainful occupation perceived their productiv-
ity to be affected by their drinking, this rate was signifi-
cantly higher among AD cases (22 %).
Table 2 Resource use data in six months before interview by alcohol dependence and sex
All patients Non-AD AD
N = 1356 male female total male female total
N = 494 N = 719 N = 1213 N = 95 N = 48 N = 143
Direct costs
Inpatient admissions a
Number of nights, mean (SD)
1.2 (5.2) 1.2 (6.0) 1.1 (4.1) 1.2 (5.0) 2.5 (7.3) 0.9 (3.4) 2.0 (6.4)
Outpatient visits a
At least one visit, % (CI)
9.9 (8.3–11.6) 8.7 (6.2–11.2) 9.9 (7.7–12.1) 9.4 (7.8–11.1) 15.8 (8.2–23.4) 10.1 (1.7–18.5) 13.9 (8.1–19.7)
Day case surgery visits a
At least one visit, % (CI)
6.0 (4.7–7.3) 4.9 (3.0–6.8) 6.0 (4.3–7.9) 5.6 (4.3–6.9) 10.1 (3.8–16.4) 8.2 (0.5–16.0) 9.5 (4.6–14.4)
Accident & emergency visits a
At least one visit, % (CI)
11.2 (9.5–12.9) 8.7 (6.2–11.2) 10.7 (8.4–13.0) 9.9 (8.2–11.6) 22.0 (13.5–30.5) 21.7 (9.8–33.6) 21.9 (15.0–28.8)
GP treatment a
Number of visits, mean (SD)
6.8 (11.4) 5.8 (9.9) 6.8 (6.4) 6.4 (8.0) 10.4 (25.6) 9.6 (24.0) 10.2 (25.1)
Prescribed medication a
Number of prescriptions,
mean (SD)
1.8 (1.5) 1.8 (1.5) 1.9 (1.5) 1.8 (1.5) 2.1 (1.5) 1.7 (1.4) 1.9 (1.5)
Home care a
At least one home visit, % (CI)
5.2 (4.0–6.4) 5.1 (3.1–7.1) 5.1 (3.5–6.8) 5.8 (3.9–6.4) 7.6 (2.2–13.1) 2.2 (0.0–6.4) 5.8 (1.9–9.8)
Alcohol treatment
At least one treatment
contact, % (CI)
1.0 (0.5–1.5) 0.4 (0.0–0.9) 0.1 (0.0–0.4) 0.2 (0.0–0.5) 9.6 (3.6–15.5) 2.3 (0.0–6.6) 7.2 (2.9–11.4)
Indirect costs
Absenteeism among
employed patients
Number of absent days,
mean (SD)
8.1 (20.4) 5.5 (15.4) 8.7 (18.4) 7.3 (17.2) 17.2 (41.1) 12.9 (26.6) 16.1 (37.9)
Unemployment
% (CI)
8.2 (6.7–9.7) 7.7 (5.3–10.0) 7.8 (5.8–9.8) 7.8 (6.2–9.3) 10.5 (4.3–16.7) 13.9 (4.3–23.6) 11.7 (6.4–16.9)
Disability/early retirement
% (CI)
16.5 (14.5–18.5) 17.6 (14.2–21.0) 14.7 (12.1–17.3) 15.8 (13.8–17.9) 22.2 (13.6–30.7) 21.6 (9.8–33.5) 22.0 (15.0–28.9)
Note
AD Alcohol dependence, SD Standard deviation, CI 95 % confidence interval, GP General practitioner
a excluding all alcohol-specific treatments (medication, inpatient and outpatient treatment, group therapy, (GP) counselling/detoxification)
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Table 3 Average direct and indirect costs per patient in six months before interview in 2014-€
All patients Non-AD AD Excess costs
N = 1356 male female total male female total male female total
N = 494 N = 719 N = 1213 N = 95 N = 48 N = 143 N = 589 N = 767 N = 1356
Direct costs
Inpatient
admissions 1a
605.53 (2446.48) 569.42 (2766.16) 543.82 (1997.69) 554.10 (2332.50) 1300.61 (3650.39) 458.99 (1634.33) 1022.95 (3165.99) 731.18 °°− −84.80 468.85 °−
Outpatient visits 1a 9.78 (26.73) 8.96 (29.28) 9.08 (20.96) 9.03 (24.59) 17.03 (45.01) 13.50 (21.81) 15.86 (39.06) 8.07 °− 4.41 6.83 °−
GP treatment 2a 219.41 (361.28) 189.23 (321.42) 217.60 (205.77) 206.22 (326.56) 336.03 (800.45) 307.33 (749.01) 326.56 (784.31) 146.81 *+ 89.73 120.34 *+
Prescribed
medication 1a
143.45 (424.96) 157.10 (521.57) 128.18 (344.64) 139.79 (423.90) 203.94 (511.76) 110.77 (152.41) 173.21 (431.74) 46.84 −17.41 33.41
Home care 1a 26.69 (226.05) 17.72 (121.62) 23.98 (148.22) 21.47 (138.34) 102.80 (661.66) 0.93 (6.14) 69.19 (546.01) 85.08 *+ −23.05 ***− 47.73
Alcohol treatment 1 11.63 (331.60) 0.36 (8.27) 0.0 (0.0) d 0.14 (5.21) 28.18 (115.97) 261.08 (1699.39) 105.01 (978.30) 27.82 °°°− 261.08 b 104.87 ***+ °°°−
Total direct costs
excluding alcohol
treatment 2
1003.68 (2609.80) 940.67 (2931.95) 921.81 (2131.66) 929.38 (2479.83) 1960.41 (3871.48) 891.52 (1913.02) 1607.77 (3400.08) 1019.74 **+ −30.29 678.39 **+
Total direct costs
including alcohol
treatment 2
1015.31 (2628.83) 941.03 (2931.86) 921.81 (2131.66) 929.53 (2479.79) 1988.59 (3869.34) 1152.59 (2507.64) 1712.79 (3508.16) 1047.56 ***+ 230.78 783.26 ***+
Indirect costs
Absenteeism
among employed
patients 1c
680.11 (1734.23) 584.05 (1542.06) 711.72 (1742.10) 660.41 (1667.00) 932.67 (2377.10) 652.28 (1684.31) 840.17 (2180.79) 348.62 *+ −59.44 179.76 *+
Unemployment 3 784.20 (2626.86) 732.85 (2570.54) 750.31 (2568.01) 743.29 (2569.20) 1008.96 (2873.82) 1335.22 (3284.69) 1116.60 (3017.16) 276.12 584.91 373.31
Disability/early
retirement 3
1402.00 (3156.06) 1445.88 (3161.93) 1281.27 (3084.52) 1347.43 (3116.68) 1824.21 (3340.81) 1888.23 (3561.13) 1845.33 (3414.18) 378.34 606.96 497.90 *+
Total indirect
costs 1
2866.31 (3833.04) 2762.78 (3772.04) 2743.30 (3788.09) 2751.13 (3782.01) 3765.85 (4062.60) 3875.72 (4152.24) 3802.10 (4092.50) 1003.07 **+ 1132.42 *+ 1050.97 ***+
Total costs
Total costs
excluding alcohol
treatment 2
3868.03 (5092.91) 3703.45 (5133.10) 3661.58 (4755.51) 3678.39 (4908.87) 5726.26 (6590.02) 4767.24 (5004.35) 5409.87 (6137.53) 2058.36 **+ 1105.66 **+ 1731.48 ***+
Total costs
including alcohol
treatment 2
3879.66 (5114.32) 3703.81 (5133.53) 3661.58 (4755.51) 3678.54 (4909.05) 5754.44 (6591.28) 5028.32 (5491.93) 5514.89 (6265.50) 2050.64 **+ 1366.74 **+ 1836.35 ***+
Note. All presented costs refer to reported and imputed costs and are presented as mean cost per patient with standard deviation in brackets
Significance of excess costs was tested with 1 zero-inflated negative binomial regressions or 2 negative binomial regressions, using alcohol dependence and age as predictors in both count (predicting values >0) and
logit (predicting 0, only for zero-inflated negative binomial regressions) model. The following symbols indicate a significant AD predictor: count model * p < .05 ** p < .01 *** p < .001; logit model + or – behind the
symbol indicates valence of respective coefficient
3 significance of excess costs was tested with age-adjusted logistic regressions for unemployment and disability (collapsing sex-specific costs into a single value). The same legend for p-values applies as for negative
binomial models
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AD Alcohol dependence, GP General practitioner
a excluding all alcohol-specific treatments (medication, inpatient and outpatient treatment, group therapy, (GP) counselling/detoxification)
b only one case with alcohol related treatment costs among female AD patients: χ2-test on contingency table with one cell having 0 counts (female non-AD patients), one cell 1 count (female AD patients): p < .001
c costs of absenteeism according to friction cost method
d no costs despite resource use because one “other alcohol contact” was specified but as the type of contact was not specified, this contact was not included in the cost calculation
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Sensitivity analysis
A one-way sensitivity analysis was conducted, varying
assumptions on costs due to absenteeism, imputation of
missing values, and annual inflation rates (see Table 5).
Results suggest that extent and significance of mean ex-
cess costs among AD cases remained significant under
all observed conditions.
Using the human capital approach yielded expectedly
higher indirect costs via absenteeism, with total costs being
8.6 % greater following this approach as compared to the
frictional cost approach. Excluding all imputed values from
cost estimations produced small changes in direct costs
(−6.4 %) and total costs (−1.6 %). Compared to sector- and
year-specific inflation rates (main calculations), estimating
the economic burden assuming 0 % or 5 % inflation led to
a 4.1 % decrease and a 5.5 % increase, respectively.
Additional analysis
Results from additional analyses examining the impact
of the diagnostic approach (GP vs. CIDI) and of different
AD severity indicators are presented in Table 6. A sig-
nificant economic burden was observed regardless of the
diagnostic approach, with significantly higher indirect
costs associated with both diagnoses. Direct costs were
found to be significantly higher among GP diagnosed pa-
tients but not among CIDI diagnosed patients.
Results of the association of various AD severity indi-
cators and incurred costs were mixed. For AD severity I,
costs were not significantly different between treated
and untreated AD cases. Similarly, no significant associ-
ation between daily drinking levels (AD severity III) and
individual costs was observed for any of the examined
cost domains. However, the only significant association
was established for the number of AUD criteria (AD se-
verity II) and indirect as well as total costs: The more
AUD criteria were met, the higher costs incurred.
Discussion
Summary
This study sought to estimate the economic burden as-
sociated with AD using a bottom-up approach with a
sample of 1356 German primary care patients. Our esti-
mations considered direct and indirect costs separately
Fig. 2 Share of excess costs of alcohol dependence by sector
0
2,000 
4,000 
6,000 
8,000 
10,000 
12,000 
18-29 30-39 40-49 50-59 60-64
Age in years
 Patients without alcohol dependence
 Patients with alcohol dependence
Total costs per patient
Fig. 1 Total costs per patient by age and AD diagnosis
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and additional analyses examined the impact of several
AD characteristics on respective costs.
In the sample studied, the economic burden of AD
was determined using excess costs which amounted to
about 1867€ per case. In other words, the direct and in-
direct costs among AD patients were about 50 % higher
compared to primary care patients without AD. Age-
and sex-stratified analyses showed that these costs were
concentrated among males and patients aged 30 to 50.
Excess costs were largely attributable to indirect costs
(57 %) in addition to costs related to inpatient treatment
(25 %). Costs reported for different kinds of alcohol
treatment made up a relatively small share, amounting
to 6 % of the excess costs. Sensitivity analysis suggests
that the estimates are robust under various assumptions.
Additional analyses indicate that increased costs were
independent of the approach to diagnose AD, as overall
costs were significantly higher among both GP and CIDI
diagnosed primary care patients, as compared to non-
AD cases. Furthermore, our results suggest that costs
may increase with AD severity but this finding was lim-
ited to the number of AUD criteria and could not be
reproduced with treatment of AD and drinking levels.
Comparison with top-down estimations
In comparison with previous top-down estimations, the
costs per patient and the breakup of direct and indirect
costs were very similar [11, 12, 21], which supports the
validity of studies using top-down methods. A more de-
tailed look at the results reveals that indirect costs were
consistently found to account for the majority of all
costs, in this sample (57 %), in a German study on
alcohol-associated costs (65 %) [12], and in a systematic
review on AD-associated economic burden in high-
income countries (72 %) [11]. However, top-down esti-
mations usually included costs due to premature mortal-
ity in their estimations, e.g. being accountable for 45 %
of all alcohol-associated costs in the above-mentioned
German study. If we adjusted indirect cost estimations
in the other studies to the same definition as used in our
study by excluding premature mortality, the share of in-
direct costs would be reduced markedly to only 20 % in
the German study and to 52 % across various high-
income countries. Thus, the reported indirect costs in
our sample were comparably high, especially compared
to the German study. This discrepancy may be explained
by differences between this sample and general popula-
tion studies, with primary care patients being older and
having more mental and physical health issues, which is
related to unemployment and claims of disability bene-
fits or early retirement pensions [58, 59]. Further, to
grant any sick leave in Germany, employers commonly
ask their employees to provide certification of illness
from a medical professional, linking absenteeism closely
to GP visits.
Implications
Our results suggest that the overwhelming majority of
the economic burden was not due to the direct treat-
ment of AD but more than 80 % was attributable to paid
absence from work, disability or early retirement, and
inpatient treatment of comorbid health problems. Given
the low treatment rates for AD (17.2 % in this sample,
see [57]) and a non-significant impact of AD treatment
Table 4 Descriptive measures of presenteeism among gainfully occupied patients
All patients Non-AD AD
N = 792 male female total male female total
N = 317 N = 403 N = 720 N = 52 N = 20 N = 72
Number of days of reduced
work in past 30 days due to any
health condition (WHODAS
2.0 H3), mean (SD)
3.0 (6.1) 2.3 (5.1) 3.3 (6.2) 2.9 (5.8) 4.0 (8.2) *+ 3.6 (7.5) 3.9 (8.0) *+
Number of days with at most
half of usual work capacity in
past 30 days due to mental
distress (K10 Q6), mean (SD)
2.0 (4.4) 1.4 (3.2) 2.1 (4.1) 1.7 (3.8) 3.2 (7.2)**+ 6.7 (8.7) 4.1 (7.7) ***+
Impaired work productivity due to drinking in past six months
At least one day, proportion
(95 % CI)
3.8 (2.5–5.2) 4.2 (2.0–6.5) 0.3 (0.0–0.8) 2.0 (1.0–3.0) 24.1 (12.2–35.9) ***+ 16.0 (0.0–32.7) **+ 21.9 (12.1–31.7) ***+
Number of days, mean (SD) 0.3 (3.1) 0.1 (0.8) 0.0 (0.1) 0.1 (0.5) 2.9 (10.8) **+ 0.4 (1.2) °°− 2.3 (9.4) **+ °−
Note
Significance between patients with and without AD was tested with zero-inflated negative binomial regressions for all count variables, using alcohol dependence
and age as predictor in both count (predicting values >0) and logit (predicting 0) model. The following symbols indicate a significant AD predictor: count model *
p < .05 ** p < .01 *** p < .001; logit model ° p < .05 °° p < .01 + or – behind the symbol indicates valence of respective coefficient
For the binary variable indicating at least one day with impaired productivity due to drinking, an age-adjusted logistic regression was conducted. The same legend
for p-values also applies to negative binomial models
AD Alcohol dependence, WHODAS World Health Organization Disability Assessment Schedule 2.0, SD Standard deviation, K10 Kessler Psychological Distress Scale,
95% CI 95 % confidence interval
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Table 5 One-way sensitivity analyses: variation of assumptions on costs of productivity, imputed values, and inflation rates
Human capital approach Only unimputed costs Annual inflation rate 0 % Annual inflation rate 5 %
Non-AD AD Total Non-AD AD Total Non-AD AD Total Non-AD AD Total
N =
1,213
N = 143 N =
1,356
N =
1,213
N = 143 N = 1,356 N = 1,213 N = 143 N = 1,356 N = 1,213 N = 143 N =
1,356
Direct costs
Total direct
costs
excluding
alcohol
treatment 1
/ / / 867.28
(2466.25)
1559.27 (3405.17) **+ 943.07 (2599.48) 800.91 (1950.23) 1371.41 (2715.12) **+ 863.40 (2059.54) 1171.80 (3393.09) 2035.01 (4551.12) **+ 1266.34
(3554.46)
Total direct
costs
including
alcohol
treatment 1
/ / / 867.42
(2466.21)
1659.84 (3511.19)
***+
954.21 (2618.22) 801.06 (1950.18) 1476.12 (2857.76)
***+
875.00 (2084.39) 1171.96 (3393.04) 2141.91 (4624.28)
***+
1278.19
(3567.83)
Indirect costs
Absenteeism 2 941.91
(3004.53)
1893.80
(6667.85)
**+
1046.24
(3626.33)
/ / / 654.52 (1652.13) 832.67 (2161.33)
*+
674.04 (1718.76) 687.24 (1734.74) 874.31 (2269.40) *+ 707.74
(1804.70)
Total indirect
costs 2
3032.64
(4400.97)
4855.73
(7102.00)
***+
3232.44
(4820.05)
/ / / 2738.60
(3766.75)
3784.64 (4073.89)
***+
2853.25
(3817.31)
2808.17 (3852.92) 3881.61 (4179.12)
***+
2925.82
(3906.19)
Total costs
Total costs
excluding
alcohol
treatment 1
3959.68
(5504.37)
6463.50
(9368.64)
***+
4233.91
(6119.86)
3616.29
(4889.88)
5361.37 (6139.02)
***+
3807.41
(5077.34)
3537.41
(4582.74)
5156.05 (5629.39)
***+
3714.69
(4740.96)
3977.80 (5583.99) 5916.62 (7106.93)
***+
4190.15
(5809.62)
Total costs
including
alcohol
treatment 1
3959.83
(5504.52)
6568.52
(9442.82)
***+
4245.54
(6137.20)
3616.43
(4890.06)
5461.94 (6268.48)
***+
3818.56
(5098.91)
3537.56
(4582.94)
5260.77 (5772.92)
***+
3726.29
(4764.30)
3977.96 (5584.17) 6023.52 (7212.45)
***+
4202.00
(5828.11)
Note. All presented costs refer to mean cost per patient with standard deviation in brackets
Imputations mainly affect the prescribed medication section, in addition to inpatient treatment, home care, and alcohol treatment
Significance of excess costs was tested with 1 negative binomial regressions or 2 zero-inflated negative binomial regressions using alcohol dependence and age as predictors in both count (predicting values >0) and
logit (predicting 0, only for zero-inflated negative binomial regressions) model. The following symbols indicate a significant AD predictor: count model * p < .05 ** p < .01 *** p < .001; logit model ° p < .05 °° p < .01 °°° p
< .001. + or – behind the symbol indicates valence of respective coefficient
AD Alcohol dependence. / = same value as in Table 1, i.e. not affected by human capital approach or by imputations
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on any cost dimension (see Additional analyses), it is not
surprising that the share of excess costs attributable to
alcohol treatment is relatively small. Low treatment rates
imply lower costs for alcohol-specific interventions but
also result in high comorbidity and continuing impair-
ment. In fact, previous studies have suggested to in-
crease treatment coverage in order to bring about
significant reductions in morbidity and mortality [60,
61], which we would expect to lead to a reduced eco-
nomic burden.
Apart from costs for alcohol treatment, inpatient
treatment and GP visits made up most of the excess
direct costs. While alcohol is a component cause of
over 200 health conditions [23, 62], AD is associated
with a wide range of physical comorbidities in in-
patient settings [8], and the present sample of AD
cases was found to be comorbid with liver diseases
and severe mental distress [57]. Thus, highly frequent
health care resource utilization and associated costs
among AD cases are not surprising and most likely
not only attributable directly to alcohol problems, but
to a significant extent to comorbidities associated
with or caused by this condition. Therefore, our find-
ings highlight and reiterate the necessity of preventing
heavy drinking over time in order to reduce respect-
ive detrimental health consequences.
Half of the excess costs were due to increased rates of
unemployment, early retirement, and disability. Further,
absenteeism was also identified as important contributor
to excess costs. While presenteeism was not part of cost
calculations in this study, it was very common among
AD cases. Some guidelines suggested the inclusion of
presenteeism in the calculation of indirect costs [63]
while others suggested not to do so [38]. In fact, many
published studies on cost-of-illness of alcohol neglected
this factor e.g. [2, 12, 15, 17] and only very few studies
included presenteeism in their estimations e.g. [64]. Our
work suggest that presenteeism is associated with AD
and should therefore be included in future studies.
A major implication of this study concerns the obser-
vation that impaired productivity represents the largest
share of the economic burden associated with AD, con-
firming previous top-down estimations from Germany
[12, 65] and elsewhere (for a review, see [66]). Public
health efforts should aim at reducing this burden while
acknowledging the bidirectional association of un-
employment and heavy drinking [67, 68] and strategies
to do so in primary health care settings have been pro-
posed [69].
Sex-stratified cost estimations in our study suggest
that excess costs mainly incurred among male AD cases
in our study. This is not only due to males representing
about two thirds of all AD cases, but rather to generally
larger cost differences in most sectors between both
sexes: Total direct costs were significantly increased in
male but not in female AD cases, and excess costs were
almost doubled among male compared to female AD
cases. While we corroborate that female AD patients are
less likely to receive treatment for their alcohol problems
than male AD patients are [70], the greater picture is ra-
ther surprising. As the small number of females in this
sample implies large confidence intervals and suscepti-
bility to outliers, these results should be carefully inter-
preted as trends. However, the results point out that
sex-stratified cost estimations are warranted and future
research should follow up these preliminary observa-
tions. Distinct sex-specific patterns of mental [71] and
somatic comorbidities [23] should be considered as po-
tential explanations for differential cost discrepancies
found in this study.
Table 6 Association of AD characteristics and individual costs
Type of AD diagnosis a AD severity I b AD severity II c AD severity III c
Excess costs: GP AD Excess costs: CIDI AD Excess costs: AD treatment IRR: DSM-5 AUD
criteria
IRR: Daily drinking
levels
N = 1,356 N = 1,356 N = 143 N = 1,356 N = 1,356
All direct costs
(95 % CI)
1132.20 (198.64–2066.09)** 322.07 (−303.93–948.08) −17.89 (−1336.70–1300.92) 1.09 (0.99–1.19) 0.99 (0.95–1.03)
All indirect costs
(95 % CI)
1947.09 (950.67–2943.52)** 355.04 (−510.20–1220.28)* 1148.41 (−688.51–2985.33) 1.12 (1.04–1.20)** 1.01 (0.98–1.04)
All costs (95 % CI) 3081.46 (1526.96–4635.96)*** 679.20 (−560.11–1918.52)** 1130.52 (−1435.05–3696.09) 1.11 (1.04–1.19)** 1.00 (0.98–1.03)
Note
AD Alcohol dependence, GP AD Alcohol dependence diagnosis by general practitioner (N = 70), CIDI AD Alcohol dependence diagnosis by the Composite
International Diagnostic Interview (N = 92), IRR Incidence risk ratio, DSM-5 AUD criteria Number of alcohol use disorder criteria as defined in the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition, 95% CI 95 % confidence interval
For testing impact of AD characteristics on different cost variables, age and sex adjusted negative binomial regressions were conducted. Legend of significance:
* p < .05 ** p < .01 *** p < .001
a Excess costs for GP AD and CIDI AD diagnoses are presented in comparison to patients without the respective diagnosis. Results based on regression using
binary predictor (no diagnosis/diagnosis) among all patients
b Excess costs between treated and untreated AD cases are presented. Results based on regression using binary predictor (untreated/treated) among all AD cases
cThe incidence risk ratios from negative binomial regressions are presented for DSM-5 AUD criteria and drinking levels. Results based on regression using continuous
predictor (severity II: number of DSM-5 AUD criteria/ severity III: daily drinking levels in standard drinks per day) among all patients
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Furthermore, our results indicate that most of the ex-
cess costs incurred among individuals aged 30 to 49,
while no substantial cost differences was observed in
younger or older cohorts. This effect is interesting and
could likely be linked to mortality, which has been
shown to be constantly high among young and middle
aged individuals with alcohol use disorders, as opposed
to the general population, for which mortality increases
steadily with age [4]. High excess costs in combination
with high mortality in these age groups support the need
of initiating treatment earlier – before somatic comor-
bidities emerge and become life-threatening [28].
Lastly, results from additional analyses show that the
economic burden is not only associated with DSM-IV
AD diagnoses but also with GP AD diagnoses, which
can be viewed as a validation for their diagnostic quality.
In addition, DSM-5 AUD severity was also found to be
associated with increased economic burden. Associa-
tions with direct costs were only found for GP AD diag-
noses and future research should examine why
associations with other AD characteristics, including
treatment and drinking levels, remained insignificant. In
this study, small sample sizes cannot be excluded as po-
tential cause.
Limitations
For a variety of reasons, the estimates in this study are
not directly comparable to a general population cost-of-
illness study. The primary reason is that this study re-
ferred to a representative sample of primary care pa-
tients, which differs considerably in its distribution of
sex and health measures from the general population.
Further, the reported estimations do not consider intan-
gible costs and costs associated with premature disability
and presenteeism – measures that should be considered
when estimating the economic burden of AD to the
whole society. In addition, further wider social costs are
evident as a result of alcohol related crime, both to the
criminal justice system and also victim costs and further
injury-related productivity costs through absenteeism.
Although these go beyond the remit of the current
study, crime costs form a substantial proportion of alco-
hol related societal costs [72–74]. Taken together, the
figures of this study are likely underestimates and should
not be generalized to the general population. Further,
stratified analyses of age, sex, and AD characteristics
should be interpreted cautiously as subgrouping results
in smaller samples, which are more susceptible to out-
liers and thereby to erroneous inferences.
With regard to valuating productivity losses, we used
the friction cost approach for absenteeism and consid-
ered transfer payments (benefits, taxation, insurances)
for unemployment, disability and early retirement. This
was a conservative decision avoiding the potential
overestimation of the true cost of productivity losses as
if using the human capital approach, and was believed to
better represent the real costs of productivity losses than
with the human capital approach, which shows the po-
tential consequences of disease for an economy in a
state of full employment equilibrium. The friction ap-
proach is also believed to prevent adverse equity impli-
cations [51, 56].
Conclusions
Despite the mentioned limitations, the present study
corroborates the importance of the economic burden as-
sociated with AD as determined by previous general
population top-down estimates by using a bottom-up
approach: Total costs were 50 % higher among patients
with AD compared to patients without this diagnosis
(excess costs: 1836€ per case), with excess costs mainly
attributable to reduced productivity. We found high
concentrations of AD-associated costs among males and
patients aged 30 to 50. Furthermore, DSM-5 AUD sever-
ity was also significantly linked to the economic burden.
While we generally confirm previous estimations of AD-
associated economic burden, we have also identified sev-
eral discrepancies. Future cost-of-illness studies using a
bottom-up approach in a general population sample may
be able to examine possible reasons for these gaps, and
they should consider presenteeism in their estimations.
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